Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CHD6 CRISPR/Cas9 KO Plasmid (h): sc-413570
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CHD6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CHD6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CHD6 Antibody (E-6): sc-393445
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CHD6 CRISPR/Cas9 KO Plasmid (h) | sc-413570 | 20 µg | $397.00 |
Overview
CHD6 (chromodomain helicase DNA-binding protein 6) is an ATP-dependent chromatin remodeler in the CHD family that couples recognition of histone marks with nucleosome repositioning to regulate transcriptional programs. It contributes to chromatin organization and DNA-templated processes, influencing RNA polymerase II–dependent gene expression and cellular responses to stress through modulation of chromatin accessibility. By shaping epigenetic states, CHD6 impacts pathways controlling differentiation, proliferation, and genome stability. Dysregulated chromatin remodeling involving CHD6 has been linked to altered transcriptional networks observed in cancer and other disorders with epigenetic dysfunction, making it a useful target for mechanistic studies.
CHD6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CHD6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CHD6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CHD6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CHD6 protein expression.
This CRISPR knockout system enables efficient generation of CHD6-deficient cell models for investigation of CHD6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CHD6 exon(s) critical for CHD6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CHD6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CHD6 CRISPR/Cas9 KO Plasmid (h) and CHD6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CHD6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CHD6 HDR Plasmid (h) and CHD6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CHD6 homology arms to support homology-directed repair at defined CHD6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.